Literature DB >> 23666043

Long-term outcome and risk factors for uncontrolled seizures after a first seizure in children with hematological malignancies.

Raja B Khan1, E Brannon Morris2, Ching-Hon Pui3, Melissa M Hudson3, Yinmei Zhou4, Cheng Cheng4, Davonna S Ledet2, Scott C Howard3.   

Abstract

Long-term outcomes of seizures that develop during treatment of childhood hematological malignancies have not been described. We analyzed seizure outcome in 62 children with leukemia or lymphoma treated at our institution. There was a median follow-up of 6.5 years since first seizure. Seizure etiology included intrathecal or systemic methotrexate in 24, leucoencephalopathy in 11, brain hemorrhage or thrombosis in 11, meningitis in 4, and no identifiable cause in 12. Seizures remained uncontrolled in 18, and risk factors for poor control included female sex (P = .02), no seizure control with first antiseizure drug (P = .08), and longer interval between cancer diagnosis and seizure onset (P = .09). Poor seizure control after initial antiseizure drug also predicted recurrent seizure after drug withdrawal (P = .04). In conclusion, seizures are controlled with medications in a majority of patients with hematological cancer. After a period without seizures, antiseizure drug withdrawal in appropriately selected patient has a high success rate.
© The Author(s) 2013.

Entities:  

Keywords:  hematological malignancy; leukemia; lymphoma; methotrexate; outcome; seizures

Mesh:

Substances:

Year:  2013        PMID: 23666043      PMCID: PMC4207712          DOI: 10.1177/0883073813488675

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  22 in total

1.  Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia.

Authors:  Laura Iuvone; Paolo Mariotti; Cesare Colosimo; Francesco Guzzetta; Antonio Ruggiero; Riccardo Riccardi
Journal:  Cancer       Date:  2002-12-15       Impact factor: 6.860

2.  Intellectual, neuropsychological, and academic functioning in long-term survivors of leukemia.

Authors:  E Raymond-Speden; G Tripp; B Lawrence; D Holdaway
Journal:  J Pediatr Psychol       Date:  2000-03

3.  Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.

Authors:  D H Mahoney; J J Shuster; R Nitschke; S Lauer; C P Steuber; B Camitta
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

4.  Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy.

Authors: 
Journal:  Epilepsia       Date:  1989 Jul-Aug       Impact factor: 5.864

5.  MR assessment of myelination in infants and children: usefulness of marker sites.

Authors:  C R Bird; M Hedberg; B P Drayer; P J Keller; R A Flom; J A Hodak
Journal:  AJNR Am J Neuroradiol       Date:  1989 Jul-Aug       Impact factor: 3.825

Review 6.  Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Authors:  J A French; A M Kanner; J Bautista; B Abou-Khalil; T Browne; C L Harden; W H Theodore; C Bazil; J Stern; S C Schachter; D Bergen; D Hirtz; G D Montouris; M Nespeca; B Gidal; W J Marks; W R Turk; J H Fischer; B Bourgeois; A Wilner; R E Faught; R C Sachdeo; A Beydoun; T A Glauser
Journal:  Neurology       Date:  2004-04-27       Impact factor: 9.910

7.  Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.

Authors:  Mark R Gilbert; Jeffrey G Supko; Tracy Batchelor; Glenn Lesser; Joy D Fisher; Steven Piantadosi; Stuart Grossman
Journal:  Clin Cancer Res       Date:  2003-08-01       Impact factor: 12.531

8.  Seizures in childhood lymphoblastic leukaemia patients.

Authors:  J J Ochs; W P Bowman; C H Pui; M Abromowitch; C Mason; J V Simone
Journal:  Lancet       Date:  1984-12-22       Impact factor: 79.321

Review 9.  Should antiepileptic drugs be withdrawn in seizure-free patients?

Authors:  Luigi M Specchio; Ettore Beghi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Intellectual outcome in children and adolescents with acute lymphoblastic leukaemia treated with chemotherapy alone: age- and sex-related differences.

Authors:  N von der Weid; I Mosimann; A Hirt; P Wacker; M Nenadov Beck; P Imbach; U Caflisch; F Niggli; A Feldges; H P Wagner
Journal:  Eur J Cancer       Date:  2003-02       Impact factor: 9.162

View more
  4 in total

1.  Seizures' impact on cognition and quality of life in childhood cancer survivors.

Authors:  Nicholas S Phillips; Raja B Khan; Chenghong Li; Sedigheh Mirzaei Salehabadi; Tara M Brinkman; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull; Zsila S Sadighi
Journal:  Cancer       Date:  2021-09-01       Impact factor: 6.860

Review 2.  Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.

Authors:  Kjeld Schmiegelow; Klaus Müller; Signe Sloth Mogensen; Pernille Rudebeck Mogensen; Benjamin Ole Wolthers; Ulrik Kristoffer Stoltze; Ruta Tuckuviene; Thomas Frandsen
Journal:  F1000Res       Date:  2017-04-07

3.  Application of Machine Learning Methods for Epilepsy Risk Ranking in Patients with Hematopoietic Malignancies Using.

Authors:  Iaroslav Skiba; Georgy Kopanitsa; Oleg Metsker; Stanislav Yanishevskiy; Alexey Polushin
Journal:  J Pers Med       Date:  2022-08-11

4.  Supportive methods for childhood acute lymphoblastic leukemia then and now: A compilation for clinical practice.

Authors:  Alexandra Podpeskar; Roman Crazzolara; Gabriele Kropshofer; Petra Obexer; Evelyn Rabensteiner; Miriam Michel; Christina Salvador
Journal:  Front Pediatr       Date:  2022-09-12       Impact factor: 3.569

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.